Lack of response in nine patients with breast cancer treated with fibroblast interferon

Bruntsch, U; Groos, Günther; Tigges, F. J.; Hofschneider, P. H.; Gallmeier, W. M.

doi:10.1007/bf00401445

Cited by 8 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Toxicity encountered in this trial consisted of fever and malaise. Bone marrow suppression, and transient elevation in liver function tests have been reported in previous studies of interferon [4,13,16,17]. Further clinical trials of other treatment schedules and dosages of interferon in the treatment of prostate cancer and other malignancies are obviously necessary to determine its role in the treatment of human malignancies.…”

Section: Discussionmentioning

confidence: 85%

Interferon‐β treatment of metastatic prostate cancer

Bulbul

Huben

Murphy

1986

Journal of Surgical Oncology

View full text Add to dashboard Cite

A limited clinical trial of Interferon-beta (Human Fibroblast Interferon) in the treatment of advanced, hormone-refractory prostate cancer was conducted by the National Prostate Cancer Project (NPCP Protocol 2100). Sixteen patients with metastatic prostate cancer who had failed prior hormone therapy were entered into the study. Treatment consisted of 6 X 10(6) units of Interferon-beta intravenously three times per week for 12 weeks. Chills and fever were seen in ten of the 16 patients (62.5%), and mild hematologic toxicity occurred in four patients. No complete or partial responses were observed. Three patients had stable disease by NPCP criteria for a mean duration of 6.3 months. Progression of disease was seen in 13 of the 16 patients, eight of whom progressed during therapy. The results of this study suggest that Interferon-beta has limited efficacy in the treatment of advanced, hormone-refractory prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 85%

Interferon‐β treatment of metastatic prostate cancer

Bulbul

Huben

Murphy

1986

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Horoszewicz et al [5] have also shown that daily injection of 0.5 x 106 IU human interferon beta into skin nodules in patients with melanoma, breast cancer, and prostate cancer results in significant reduction of growth in about half of those tumor nodules treated. However, Bruntsch and co-workers [6] saw no anti-tumor responses in nine patients with metastatic breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Phase II trial of recombinant Beta (IFN-Betaser) interferon in the treatment of metastatic breast cancer

et al. 1988

View full text Add to dashboard Cite

Nine patients with metastatic breast cancer received 30 x 10(6) I.U. of Interferon - Betaser (Betaseron) intravenously daily times five for two consecutive weeks followed by a two week rest period. Only one patient received more than one such cycle of Betaseron. The drug was well tolerated in eight of these patients. One patient, with liver metastases and liver dysfunction, developed hepatic decompensation during therapy. Toxicity consisted of anorexia, chills, fever, fatigue and nausea with an occasional patient having emesis. One patient developed severe thrombocytopenia, two, significant leukopenia and nine, mild elevations of serum transaminase. Two patients developed beta interferon binding antibodies but none developed neutralizing antibodies. No anti-tumor responses were seen and disease progression occurred rapidly during the four week cycle in eight of nine patients.

show abstract

“…In another study, natural and recombinant IFNs-[5 proved to be more effective than IFN-a in inhibiting the growth of one human breast cancer cell line transplanted into nude mice, while the opposite was true for another mammary carcinoma xenograft [16]. Clinically, the results of treatments with IFN-[5 were reported to vary from no objective remissions [17] to partial [18][19][20] or complete [20] responses in selected patients with metastatic or recurrent breast carcinomas.…”

Section: Introductionmentioning

confidence: 93%

Antiproliferative effects of natural interferon beta alone and in combination with natural interferon gamma on human breast carcinomas in nude mice

Ozzello

1990

Breast Cancer Res Tr

View full text Add to dashboard Cite

Nude mice bearing bilateral xenografts of human breast carcinoma cells (MCF-7 and BT20) were treated with 2 or 45-day cycles of intralesional (i.l.) injections of human natural interferon beta (nIFN-beta) alone or in combination with human natural interferon gamma (nIFN-gamma). The injections were administered to only 1 of the 2 tumors in each animal, thus making it possible to assess at the same time local therapeutic effects in the injected tumors and systemic effects in the contralateral ones. When n-IFN-beta was used as a single agent only mild local antitumor effects and virtually no systemic effects were observed. In contrast, the combined administration of nIFN-beta/nIFN-gamma produced marked antiproliferative effects, presumably as a result of the synergistic action of type I and type II IFNs. These effects ranged from complete regression documented histologically in 2 MCF-7 tumors to varying degrees of growth inhibition with persistence of residual microscopic or grossly detectable tumor. Local effects were more pronounced than systemic effects. The therapeutic efficacy of nIFN-beta proved to be greater than that of recombinant interferon beta (rIFN-beta). In MCF-7 tumors nIFN-beta appeared to be less effective than nIFN-alpha, whereas the opposite was true for BT20 tumors.

show abstract

Lack of response in nine patients with breast cancer treated with fibroblast interferon

Cited by 8 publications

References 15 publications

Interferon‐β treatment of metastatic prostate cancer

Interferon‐β treatment of metastatic prostate cancer

Phase II trial of recombinant Beta (IFN-Betaser) interferon in the treatment of metastatic breast cancer

Antiproliferative effects of natural interferon beta alone and in combination with natural interferon gamma on human breast carcinomas in nude mice

Contact Info

Product

Resources

About